GSK Highlights Immuno-Oncology Focus with Adaptimmune Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 4 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2049 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
GlaxoSmithKline (GSK) has agreed to collaborate with UK-based Adaptimmune to co-develop cancer immunotherapies using its affinity-enhanced T-cell receptor (TCR) engineering technology, including the company’s lead clinical programme targeting the cancer testis antigen NY-ESO-1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS